Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Phosphorylation of TSC2 by PKC-δ reveals a novel signaling pathway that couples protein synthesis to mTORC1 activity.

Zhan J, Chitta RK, Harwood FC, Grosveld GC.

Mol Cell Biochem. 2019 Jun;456(1-2):123-134. doi: 10.1007/s11010-019-03498-8. Epub 2019 Jan 25.

PMID:
30684133
2.

Establishment of a transgenic mouse to model ETV7 expressing human tumors.

Numata M, Klein Geltink RI, Grosveld GC.

Transgenic Res. 2019 Feb;28(1):115-128. doi: 10.1007/s11248-018-0104-z. Epub 2018 Nov 27.

3.

ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer.

Harwood FC, Klein Geltink RI, O'Hara BP, Cardone M, Janke L, Finkelstein D, Entin I, Paul L, Houghton PJ, Grosveld GC.

Sci Adv. 2018 Sep 12;4(9):eaar3938. doi: 10.1126/sciadv.aar3938. eCollection 2018 Sep.

4.

Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease.

Lagutina IV, Valentine V, Picchione F, Harwood F, Valentine MB, Villarejo-Balcells B, Carvajal JJ, Grosveld GC.

PLoS Genet. 2015 Feb 6;11(2):e1004951. doi: 10.1371/journal.pgen.1004951. eCollection 2015.

5.

Zebrafish ETV7 regulates red blood cell development through the cholesterol synthesis pathway.

Quintana AM, Picchione F, Klein Geltink RI, Taylor MR, Grosveld GC.

Dis Model Mech. 2014 Feb;7(2):265-70. doi: 10.1242/dmm.012526. Epub 2013 Dec 19.

6.

Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells.

Blum JM, Añó L, Li Z, Van Mater D, Bennett BD, Sachdeva M, Lagutina I, Zhang M, Mito JK, Dodd LG, Cardona DM, Dodd RD, Williams N, Ma Y, Lepper C, Linardic CM, Mukherjee S, Grosveld GC, Fan CM, Kirsch DG.

Cell Rep. 2013 Nov 27;5(4):933-40. doi: 10.1016/j.celrep.2013.10.020. Epub 2013 Nov 14.

7.

PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis.

Marshall AD, Picchione F, Geltink RI, Grosveld GC.

Neoplasia. 2013 Jul;15(7):738-48.

8.

Mapping of MN1 sequences necessary for myeloid transformation.

Kandilci A, Surtel J, Janke L, Neale G, Terranova S, Grosveld GC.

PLoS One. 2013 Apr 23;8(4):e61706. doi: 10.1371/journal.pone.0061706. Print 2013.

9.

Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis.

Marshall AD, Grosveld GC.

Skelet Muscle. 2012 Dec 3;2(1):25. doi: 10.1186/2044-5040-2-25.

10.

The leukemia-associated fusion protein MN1-TEL blocks TEL-specific recognition sequences.

ter Haar WM, Meester-Smoor MA, van Wely KH, Schot CC, Janssen MJ, Geverts B, Bonten J, Grosveld GC, Houtsmuller AB, Zwarthoff EC.

PLoS One. 2012;7(9):e46085. doi: 10.1371/journal.pone.0046085. Epub 2012 Sep 26.

11.

PAX3-FOXO1 induces cannabinoid receptor 1 to enhance cell invasion and metastasis.

Marshall AD, Lagutina I, Grosveld GC.

Cancer Res. 2011 Dec 15;71(24):7471-80. doi: 10.1158/0008-5472.CAN-11-0924. Epub 2011 Oct 28.

12.

PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.

Marshall AD, van der Ent MA, Grosveld GC.

Mol Carcinog. 2012 Oct;51(10):807-15. doi: 10.1002/mc.20848. Epub 2011 Aug 31.

PMID:
21882254
13.

IRIZIO: a novel gene cooperating with PAX3-FOXO1 in alveolar rhabdomyosarcoma (ARMS).

Picchione F, Pritchard C, Lagutina I, Janke L, Grosveld GC.

Carcinogenesis. 2011 Apr;32(4):452-61. doi: 10.1093/carcin/bgq273. Epub 2010 Dec 22.

14.

Reintroduction of CEBPA in MN1-overexpressing hematopoietic cells prevents their hyperproliferation and restores myeloid differentiation.

Kandilci A, Grosveld GC.

Blood. 2009 Aug 20;114(8):1596-606. doi: 10.1182/blood-2009-02-205443. Epub 2009 Jun 26.

15.

Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.

Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld GC, Wells SI.

Cancer Res. 2009 Mar 1;69(5):1792-9. doi: 10.1158/0008-5472.CAN-08-2304. Epub 2009 Feb 17.

16.

Gamma-secretase inhibitors: Notch so bad.

Grosveld GC.

Nat Med. 2009 Jan;15(1):20-1. doi: 10.1038/nm0109-20. No abstract available.

17.

MN1 affects expression of genes involved in hematopoiesis and can enhance as well as inhibit RAR/RXR-induced gene expression.

Meester-Smoor MA, Janssen MJ, Grosveld GC, de Klein A, van IJcken WF, Douben H, Zwarthoff EC.

Carcinogenesis. 2008 Oct;29(10):2025-34. doi: 10.1093/carcin/bgn168. Epub 2008 Jul 16.

18.

Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice.

Kawagoe H, Kandilci A, Kranenburg TA, Grosveld GC.

Cancer Res. 2007 Nov 15;67(22):10677-85.

19.

MN1, a novel player in human AML.

Grosveld GC.

Blood Cells Mol Dis. 2007 Nov-Dec;39(3):336-9. Epub 2007 Aug 14. Review.

20.

SET-CAN, the product of the t(9;9) in acute undifferentiated leukemia, causes expansion of early hematopoietic progenitors and hyperproliferation of stomach mucosa in transgenic mice.

Ozbek U, Kandilci A, van Baal S, Bonten J, Boyd K, Franken P, Fodde R, Grosveld GC.

Am J Pathol. 2007 Aug;171(2):654-66. Epub 2007 Jun 14.

21.

MN1 overexpression is an important step in the development of inv(16) AML.

Carella C, Bonten J, Sirma S, Kranenburg TA, Terranova S, Klein-Geltink R, Shurtleff S, Downing JR, Zwarthoff EC, Liu PP, Grosveld GC.

Leukemia. 2007 Aug;21(8):1679-90. Epub 2007 May 24.

PMID:
17525718
22.

The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription.

van Wely KH, Meester-Smoor MA, Janssen MJ, Aarnoudse AJ, Grosveld GC, Zwarthoff EC.

Oncogene. 2007 Aug 23;26(39):5733-40. Epub 2007 Mar 19.

PMID:
17369854
23.

The MN1 oncoprotein activates transcription of the IGFBP5 promoter through a CACCC-rich consensus sequence.

Meester-Smoor MA, Molijn AC, Zhao Y, Groen NA, Groffen CA, Boogaard M, van Dalsum-Verbiest D, Grosveld GC, Zwarthoff EC.

J Mol Endocrinol. 2007 Feb;38(1-2):113-25.

PMID:
17242174
24.

MN1-TEL, the product of the t(12;22) in human myeloid leukemia, immortalizes murine myeloid cells and causes myeloid malignancy in mice.

Carella C, Bonten J, Rehg J, Grosveld GC.

Leukemia. 2006 Sep;20(9):1582-92. Epub 2006 Jun 29.

PMID:
16810199
25.

The ETS factor TEL2 is a hematopoietic oncoprotein.

Carella C, Potter M, Bonten J, Rehg JE, Neale G, Grosveld GC.

Blood. 2006 Feb 1;107(3):1124-32. Epub 2005 Oct 18.

26.

FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.

Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveld GC.

J Cell Biol. 2005 Sep 12;170(6):903-12. Retraction in: Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveldz GC. J Cell Biol. 2007 May 7;177(3):563.

27.

FoxO1a-cyclic GMP-dependent kinase I interactions orchestrate myoblast fusion.

Bois PR, Brochard VF, Salin-Cantegrel AV, Cleveland JL, Grosveld GC.

Mol Cell Biol. 2005 Sep;25(17):7645-56.

28.
30.
31.

The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.

Cardone M, Kandilci A, Carella C, Nilsson JA, Brennan JA, Sirma S, Ozbek U, Boyd K, Cleveland JL, Grosveld GC.

Mol Cell Biol. 2005 Mar;25(6):2395-405.

33.

FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts.

Bois PR, Grosveld GC.

EMBO J. 2003 Mar 3;22(5):1147-57.

34.

The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription.

van Wely KH, Molijn AC, Buijs A, Meester-Smoor MA, Aarnoudse AJ, Hellemons A, den Besten P, Grosveld GC, Zwarthoff EC.

Oncogene. 2003 Feb 6;22(5):699-709.

PMID:
12569362
35.

Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo.

Inoue A, Seidel MG, Wu W, Kamizono S, Ferrando AA, Bronson RT, Iwasaki H, Akashi K, Morimoto A, Hitzler JK, Pestina TI, Jackson CW, Tanaka R, Chong MJ, McKinnon PJ, Inukai T, Grosveld GC, Look AT.

Cancer Cell. 2002 Oct;2(4):279-88.

36.

Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors.

Lagutina I, Conway SJ, Sublett J, Grosveld GC.

Mol Cell Biol. 2002 Oct;22(20):7204-16.

37.

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.

Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP.

Nat Med. 2001 Sep;7(9):1028-34.

PMID:
11533706
38.

The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity.

Buijs A, van Rompaey L, Molijn AC, Davis JN, Vertegaal AC, Potter MD, Adams C, van Baal S, Zwarthoff EC, Roussel MF, Grosveld GC.

Mol Cell Biol. 2000 Dec;20(24):9281-93.

40.

Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells.

Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, Hoffmeyer A, van Deursen J, Sangster MY, Bunting KD, Grosveld GC, Ihle JN.

Immunity. 1999 Feb;10(2):249-59.

41.

12p abnormalities and the TEL gene (ETV6) in childhood acute lymphoblastic leukemia.

Raimondi SC, Shurtleff SA, Downing JR, Rubnitz J, Mathew S, Hancock M, Pui CH, Rivera GK, Grosveld GC, Behm FG.

Blood. 1997 Dec 1;90(11):4559-66.

42.

The nucleoporin CAN/Nup214 binds to both the cytoplasmic and the nucleoplasmic sides of the nuclear pore complex in overexpressing cells.

Boer JM, van Deursen JM, Croes HJ, Fransen JA, Grosveld GC.

Exp Cell Res. 1997 Apr 10;232(1):182-5.

PMID:
9141635
43.

Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells.

Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT, Sangster MY, Vignali DA, Doherty PC, Grosveld GC, Ihle JN.

Nature. 1996 Jul 11;382(6587):171-4.

PMID:
8700208
44.

Defective lymphoid development in mice lacking Jak3.

Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, Doherty PC, Grosveld GC, Ihle JN.

Science. 1995 Nov 3;270(5237):800-2. Erratum in: Science 1996 Jan 5;271(5245):17.

PMID:
7481769
45.

Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells.

Zhou XY, Morreau H, Rottier R, Davis D, Bonten E, Gillemans N, Wenger D, Grosveld FG, Doherty P, Suzuki K, Grosveld GC, d'Azzo A.

Genes Dev. 1995 Nov 1;9(21):2623-34.

46.

Genetic heterogeneity in tuberous sclerosis.

Janssen LA, Sandkuyl LA, Merkens EC, Maat-Kievit JA, Sampson JR, Fleury P, Hennekam RC, Grosveld GC, Lindhout D, Halley DJ.

Genomics. 1990 Oct;8(2):237-42.

PMID:
1979047
47.

Detection of the Philadelphia chromosome in interphase nuclei.

Arnoldus EP, Wiegant J, Noordermeer IA, Wessels JW, Beverstock GC, Grosveld GC, van der Ploeg M, Raap AK.

Cytogenet Cell Genet. 1990;54(3-4):108-11.

PMID:
2265553
48.

Absence of alternative splicing in bcr-abl mRNA in chronic myeloid leukemia cell lines.

Hermans A, Selleri L, Gow J, Grosveld GC.

Blood. 1988 Dec;72(6):2066-9.

49.

Translocation of c-abl to "masked" Ph in chronic myeloid leukemia.

Hagemeijer A, de Klein A, Gödde-Salz E, Turc-Carel C, Smit EM, van Agthoven AJ, Grosveld GC.

Cancer Genet Cytogenet. 1985 Oct;18(2):95-104.

PMID:
3863697
50.

Sequence requirements for the transcription of the rabbit beta-globin gene in vivo: the -80 region.

Grosveld GC, Rosenthal A, Flavell RA.

Nucleic Acids Res. 1982 Aug 25;10(16):4951-71.

Supplemental Content

Loading ...
Support Center